Literature DB >> 20877666

ASCO 2009: What's New in Breast Cancer Therapy?

Laura Biganzoli1, Hervé Bonnefoi, Fatima Cardoso, Robert Coleman, Beat Thürlimann.   

Abstract

Entities:  

Year:  2009        PMID： 20877666      PMCID： PMC2941658          DOI： 10.1159/000230677

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  8 in total

Review 1.  Oral bisphosphonates as adjuvant therapy for operable breast cancer.

Authors:  Trevor Powles; Eugene McCroskey; Alexander Paterson
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Authors:  Nicholas J Robert; Véronique Diéras; John Glaspy; Adam M Brufsky; Igor Bondarenko; Oleg N Lipatov; Edith A Perez; Denise A Yardley; Stephen Y T Chan; Xian Zhou; See-Chun Phan; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

3.  Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.

Authors:  I J Diel; A Jaschke; E F Solomayer; C Gollan; G Bastert; C Sohn; F Schuetz
Journal:  Ann Oncol       Date:  2008-07-29       Impact factor: 32.976

4.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Authors:  Michael Gnant; Brigitte Mlineritsch; Walter Schippinger; Gero Luschin-Ebengreuth; Sabine Pöstlberger; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Vesna Bjelic-Radisic; Hellmut Samonigg; Christoph Tausch; Holger Eidtmann; Günther Steger; Werner Kwasny; Peter Dubsky; Michael Fridrik; Florian Fitzal; Michael Stierer; Ernst Rücklinger; Richard Greil; C Marth
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

5.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Authors:  Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

6.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

7.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

8.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.